Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)

May 13, 2017 by in GYNECOLOGY Comments Off on Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)

Objective To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas (USC) cell lines. To assess the efficacy of GDC-0980, a potent inhibitor…

read more

Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals

May 13, 2017 by in GYNECOLOGY Comments Off on Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals

Objective Regulatory bodies and insurers evaluate hospital quality using obstetrical outcomes, however meaningful comparisons should take preexisting patient characteristics into account. Furthermore, if risk-adjusted outcomes are consistent within a hospital, fewer…

read more
Get Clinical Tree app for offline access